Ann: Letter to Shareholders, page-89

And these posts are what Ignore was invented for. But anyway. Everyone is jumping at shadows right now. How about we look at the facts?

The cost of executing a pipeline of trials and activities was fully accounted for and the CR was oversubscribed.

Outgoing roles match incoming new hires' salaries.

Companies receive R&D refunds that become contingency cash for donations, travel, additional research opportunities.

RAC are in a great financial position. If more capital is required, I would think we're about ready to be talking to potential suitors about mutually beneficial financial arrangements based on "our exceptional pre-clinical database". The scale of future clinical sites would require investment beyond what Aussie investors are capable of putting in - or based on some of the commentary on here, capable of understanding deeply enough to appreciate value or timelines.